苏合香丸治疗急性脑梗死后运动性失语症临床疗效及安全性观察  

Clinical Efficacy and Safety Observation of Suhexiang Pill(苏合香丸)in the Treatment of Motor Aphasia after Acute Cerebral Infarction

作　　者：管冬梅 王德俊[2] 王东新 阮明军 刘占国 GUAN Dongmei;WANG Dejun;WANG Dongxin;RUAN Mingjun;LIU Zhanguo(Shandong University of Traditional Chinese Medicine,Jinan 250355,Shandong,China;Jining Hospital of Traditional Chinese Medicine,Jining 272000,Shandong,China;Jining City Hospital of Integrated Chinese and Western Medicine,Jining 272067,Shandong,China)

机构地区：[1]山东中医药大学,山东济南250355 [2]济宁市中医院,山东济宁272000 [3]济宁市中西医结合医院,山东济宁272067

出　　处：《辽宁中医药大学学报》2024年第11期197-201,共5页Journal of Liaoning University of Traditional Chinese Medicine

基　　金：山东省中医药科技项目(2020M156)。

摘　　要：目的观察苏合香丸治疗急性脑梗死后运动性失语症(痰浊蒙窍型)的临床疗效及其安全性。方法将2021年10月—2023年11月济宁市中医院与济宁市中西医结合医院脑病科病房收治的80例急性脑梗死后运动性失语症(痰浊蒙窍型)患者随机分为对照组(40例)和观察组(40例)。两组均予以内科常规疗法,观察组在对照组基础上予以口服苏合香丸,均治疗2周。比较两组患者治疗前后的汉语标准失语症检查表(CRRCAE)评分、脑卒中失语生活质量量表(SAQOL-39)评分、美国国立卫生研究院卒中量表(NIHSS)评分、中医证候积分、神经元特异性烯醇化酶(NSE)、白细胞介素-6(IL-6)以及超敏C反应蛋白(hs-CRP)变化,评定临床疗效,并记录两组患者不良反应情况。结果观察组总有效率为90.0%,显著高于对照组的67.5%(P<0.05);两组患者治疗前CRRCAE评分、SAQOL-39评分、NIHSS评分、NSE、IL-6、hs-CRP以及中医证候积分比较差异无统计学意义(P>0.05),治疗后两组患者CRRCAE评分、SAQOL-39评分、NIHSS评分、NSE、IL-6、hs-CRP及中医证候积分较治疗前均有显著改善(P<0.05),其中观察组治疗后CRRCAE评分、SAQOL-39评分、NSE、hs-CRP及中医证候积分均显著优于对照组(P<0.05),但观察组NIHSS评分及血清IL-6水平较对照组差异无统计学意义(P>0.05)。结论苏合香丸治疗急性脑梗死后运动性失语症(痰浊蒙窍型)临床疗效显著,且无明显不良反应,值得临床推广应用。Objective To observe the clinical efficacy and safety of Suhexiang Pill(苏合香丸)in the treatment of motor aphasia after acute cerebral infarction.Methods From October 2021 to November 2023,80 patients with motor aphasia after acute cerebral infarction were randomly divided into control group(40 cases)and observation group(40 cases).Both groups were given conventional medical treatment,and the observation group was given oral Suhexiang pill on the basis of the control group for 2 weeks.Chinese Standard Aphasia Checklist(CRRCAE)score,Stroke Aphasia Quality of Life Scale(SAQOL-39)score,National Institutes of Health Stroke Scale(NIHSS)score,TCM syndrome symptom score,neuron-specific enolase(NSE),interleukin-6(IL-6)and hypersensitive C reaction were compared between the two groups before and after treatment-6 The clinical efficacy was evaluated and the adverse reactions of the two groups were recorded.Results The total effective rate of observation group was 90.0%,which was significantly higher than that of control group(67.5%)(P<0.05).There was no statistical significance in CRRCAE score,SAQOL-39 score,NIHSS score,IL-6,NSE,IL-6,hs-CRP and TCM syndrome symptom score between the two groups before treatment(P>0.05).After treatment,the CRRCAE score,SAQOL-39 score,NIHSS score,NSE,hs-CRP and TCM syndrome symptom score of the two groups were significantly improved compared with before treatment(P<0.05).After treatment,CRRCAE score,SAQOL-39 score,NSE,hs-CRP and TCM syndrome symptom score of observation group were significantly better than those of control group(P<0.05).But the NIHSS score and serum IL-6 level of the observation group had no statistical significance compared with the control group(P>0.05).No serious adverse reactions were reported in either group.Conclusion Suhexiang Pill has significant clinical effect on motor aphasia after acute cerebral infarction(phlegm turbidity covering orifice syndrome),and no obvious adverse reactions,which is worthy of clinical application.

关 键 词：脑梗死 运动性失语症 苏合香丸 痰浊蒙窍 临床研究 

分 类 号：R255.2[医药卫生—中医内科学] R767.64[医药卫生—中医学]